News | September 18, 2007

Ischemic HF Patients Respond Better to PET-guided CRT Lead Placement

September 18, 2007- With PET-guided lead placement, cardiac resynchronization therapy (CRT) can achieve significant clinical improvement in patients with severe ischemic heart failure, even in the presence of extensive scarring, reported investigators at the American Society of Nuclear Cardiology meeting, held in San Diego, CA, from September 6 – 9.

The preliminary study found that two-thirds of patients responded to therapy, despite evidence that CRT works only in patients with nonischemic heart failure, indicated Lucie Riedlbauchova, M.D., the Institute for Clinical and Experimental Medicine in Prague, Czech Republic.

"Our results show that CRT-associated reverse remodeling can be expected even in patients with extensive left ventricular scarring," said Dr. Riedlbauchova. "Using PET to place CRT leads remotely from the scar is associated with a more sizeable treatment effect."

The study involved 66 CRT patients with documented stenosis of 60 percent or more in at least one coronary artery (or a history of myocardial infarction), who received PET exams using both rubidium-82 perfusion imaging and 18F-FDG viability assessment prior to CRT implantation. The median follow-up was 16 months.
According to investigaors, lead placement and pacing remotely from scar area led to significant improvement in NYHA classification and to reverse remodeling. Myocardial hibernation or ischemia at the site of pacing did not affect the therapeutic impact of CRT.
The nonresponse rate was 35 percent, despite the presence of extensive left ventricular scarring in the patient population. Twenty patients died during follow-up, 14 of whom were nonresponders. Among the patients who died, the time from CRT implantation to death was significantly longer in patients who had responded to resynchronization therapy (34 months versus 9 months in nonresponders, P=0.01) and in patients who had scarring that involved less than 25 percent of the left ventricle (P=0.01 versus more extensive scarring).

For more information: www.asnc.org


Related Content

News | PET Imaging

June 18, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Home June 18, 2024
Home
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Home June 14, 2024
Home
News | PET Imaging

October 5, 2023 — Jubilant DraxImage Inc., a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an ...

Home October 05, 2023
Home
News | PET Imaging

December 1, 2022 — A new method for determining whether patients with heart disease need coronary stents or bypass ...

Home December 01, 2022
Home
News | PET Imaging

September 14, 2022 — GE Healthcare and Lantheus Holdings Inc have announced that the recent Phase III clinical trial of ...

Home September 14, 2022
Home
News | PET Imaging

August 25, 2022 — The results of “A Phase 3, Open-label, Multicenter Study of Flurpiridaz (F18) Injection for Positron ...

Home August 25, 2022
Home
News | PET Imaging

June 15, 2022 — Poor functional outcomes after a heart attack can be predicted with a new PET imaging agent, 68Ga-FAPI ...

Home June 15, 2022
Home
Technology | PET Imaging

December 5, 2018 — Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market ...

Home December 05, 2018
Home
News | PET Imaging

July 17, 2018 — A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new ...

Home July 17, 2018
Home
News | PET Imaging

July 7, 2017 — Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are ...

Home July 07, 2017
Home
Subscribe Now